Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
Status:
Completed
Trial end date:
2016-12-14
Target enrollment:
Participant gender:
Summary
This study is to investigate the efficacy, safety, and Pharmacokinetics (PK) of Inhaled
Iloprost (Ventavis) therapy in Japanese pulmonary arterial hypertension (PAH) patients in
Main Treatment Phase (12 weeks) and to investigate the safety, tolerability, and efficacy of
longterm Inhaled Iloprost (Ventavis) therapy in Japanese PAH patients in Extension Phase.